Lumos Diagnostics (ASX:LDX) has announced that it has received confirmation of reimbursement coverage from two additional Medicare Administrative Contractors (MACS), First Coast Service Options (FCSO) and Noridian Healthcare Solutions (Noridian).
The company said FebriDx will be included in FCSO and Noridian's Medicare Fee Schedule retrospectively from 1 April 2025. FCSO manages Medicare payments in Florida, while Noridian provides coverage across a wide geographic region that includes California, Nevada, Oregon, Washington, Idaho, Montana, Utah, Arizona, Wyoming, North Dakota, South Dakota, Alaska, and Hawaii.
With the inclusion of these two MACs, to the previously announced coverage from Novitas and Palmetto, Lumos now has Medicare reimbursement from four of the seven MACs, representing over 55 per cent of the total US Medicare payment coverage.
FebriDx is a rapid point-of-care test that uses a fingerstick blood sample to differentiate bacterial infection and non-bacterial etiology. FebriDx is intended to be used in urgent and emergency care settings.
Doug Ward, the managing director of Lumos Diagnostics, said, “Securing additional Medicare coverage from FCSO and Noridian for FebriDx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients, but also integrates seamlessly into care pathways and delivers value to the broader health system.
“Lumos remains committed to securing adoption from the remaining three MACs and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
